A Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Azetukalner in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression)
Фаза 3 – широко изпитване преди одобрение
Заболявания:
Depressive episodes associated with Bipolar disorder I or II (Bipolar Depression)
Спонсор: Xenon Pharmaceuticals Inc.
Налично на:
БГ
Обобщение
Trial status: Authorised
Change from baseline in the CGI-S score at Week 6., Change from baseline in the MADRS total score at Week 1., Change from baseline in the SHAPS total score at Week 6.
Change from baseline in the MADRS total score at Week 6.
Описание
Change from baseline in the CGI-S score at Week 6., Change from baseline in the MADRS total score at Week 1., Change from baseline in the SHAPS total score at Week 6.
Кой може да участва
Age group: 65+ years, 18-64 years
Gender: Female, Male
Target enrollment: 123 participants
БГ
EN